Evaxion A/S (EVAX)

In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares of micro-cap AI immunology firm Evaxion A/S (NASDAQ:EVAX).

Evaxion Biotech A/S (NASDAQ:EVAX) Q1 2026 Earnings Call Transcript May 7, 2026Evaxion Biotech A/S reports earnings inline with expectations. Reported EPS is $-0.01 EPS, expectations were $-0.01.

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for standing by.

Evaxion Biotech A/S (NASDAQ:EVAX) Q3 2025 Earnings Call Transcript November 6, 2025 Operator: Hello, and welcome to the Evaxion Business Update and Third Quarter 2025 Financial Results.

Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential.

On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2025 Earnings Call Transcript August 19, 2025 Operator: Hello, and welcome to Evaxion's Second Quarter 2025 Conference Call.

The Gates Foundation has awarded Evaxion A/S (NASDAQ:EVAX) a grant to use its exclusive AI-Immunology™ technology to develop a new polio vaccine.

Evaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call Transcript May 27, 2025 Christian Kanstrup - CEO: Birgitte Rono - Chief Scientific Officer: Thomas Schmidt - CFO: Operator: Good day, and thank ...